arrow
R

Roni Shouval

Memorial Sloan Kettering Cancer Center
H指数:37
被引数:4,773

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia

异基因移植后急性白血病患者无白血病生存的综合性预后模型

2026-07-020
OA
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells

专家小组评审及工程化免疫效应细胞生物标志物检测的实用指南

2026-05-160
OAAI
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell Lymphoma

基于里程碑的CD19 CAR T细胞疗法后大型B细胞淋巴瘤的长期预后评估

2026-02-280
PRE
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9作为一种新型预后标志物,用于识别患有噬血细胞性淋巴组织细胞增多症的成人高风险群体。

Blood
IF23.1
2026-02-263
PRE
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

CD19 CAR-T疗法后大B细胞淋巴瘤患者糖皮质激素使用模式与安全性

2025-11-010
OAAI
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia

CD19 CAR T细胞疗法在Richter转化中的研究:欧洲慢性淋巴细胞白血病研究倡议进行的 multicentre 回顾性分析

2025-10-220
OAAI
Artificial Intelligence in Hematology

血液学中的人工智能

Blood
IF23.1
2025-08-260
PRE
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

CD19靶向CAR T细胞疗法在大型B细胞淋巴瘤中的比较真实世界结果

2025-08-190
OAAI
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma

新型合并症指数与大型B细胞淋巴瘤嵌合抗原受体T细胞治疗后生存期的关联

2025-08-180
OAAI
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Barriers to Chimeric Antigen Receptor T-Cell Therapy

嵌合抗原受体T细胞疗法中的障碍

2025-05-150
PRE